Modern source after positive coronavirus vaccine trial

Modern Inc. (mRNA) – Get Report Pre-market trading gained momentum on Wednesday. The drugmaker reported equally positive data from initial testing of his experimental coronavirus vaccine.

Modern said that Phase I trial of mRNA-1273, its proposed coronavirus vaccine candidate, antibody responses in all 45 patient participants, with no serious side effects, over a period of four weeks after two injections. The results open the door to a large study of some 30,000 patients to be held on July 27, and follow positive results in a vaccine study reported earlier this week by drugmaker Pfizer Inc. (PFE) – Get Report.